America's obesity rate fell from 39.9% to 36.4% as GLP-1 use climbed

America's adult obesity rate fell from 39.9% in 2022 to 36.4% in 2026, and over the same stretch the share of adults taking a GLP-1 for weight loss went from 3% to 11%, or one in nine, up from one in 33. Gallup put the question to 5,065 US adults between 28 May and 5 June 2026 and found 15% have taken one at some point, nine percentage points more than two years ago.

Food manufacturers do not need the science settled to act on it. A separate analysis published in Nature this year found obesity's decades-long rise is plateauing across developed nations while it keeps accelerating in developing ones, which reads less like a blip than like the first real bend in that curve in living memory. For a food industry whose largest customer base is now eating differently, that is a planning problem rather than a headline.

Correlation is not proof, and obesity is shaped by income, genetics, activity levels and policy as well as by medication. That does not mean the medicines explain the drop on their own, and the alignment breaks in at least one place: adults aged 65 and over report the drugs working less well for them. The harder question for a food culture built on abundance is what people want from a meal once they need less of it.

Read the full story at Bakery & Snacks ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.